Pfizer has sold more than half of its shareholding in BioNTech, the German biotechnology company with which it co-developed the highly successful COVID-19 vaccine, Comirnaty. After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.

This divestment comes several years after the vaccine’s peak commercial success, when it generated record global sales. Despite the reduction in equity, BioNTech has confirmed that its partnership with Pfizer—covering both commercial operations and ongoing development work—remains fully intact.

The move indicates a broader strategic shift at Pfizer as it focuses on new pipeline opportunities and future growth areas, especially at a time when the company faces pressure from patent expiries and intensifying competition across its portfolio.